NJHA Charts Rise and Fall of COVID Hospitalizations; Peak Occurred April 14

NJHA: A new bulletin from the New Jersey Hospital Association reviews the “rise and fall” of COVID-19 in New Jersey hospitals, charting the peak day of hospital activity on April 14 and the steady decline that is bringing the state’s hospitals close to pre-COVID capacity levels.

New Jersey reported its first COVID-19 case on March 4. The rapid rise of the virus in New Jersey culminated on April 14, when the state’s hospitals experienced the following peaks:

  • 8,084 patients were hospitalized with COVID-19
  • 82 percent of intensive care beds were filled
  • 62 percent of ventilators were in use.

These numbers represent a statewide average. However, COVID-19 activity varied significantly across regions of the state, with some facilities in northern New Jersey near 100 percent of capacity in mid-April.

The bulletin includes data through May 20, when 3,208 patients were hospitalized with COVID-19. That’s a 60 percent decline from hospitals’ peak.

“One of the greatest fears – that COVID cases would exceed our available beds and ventilators – never materialized, thanks to hospitals’ nimbleness in expanding capacity in our healthcare system,” said NJHA President and CEO Cathy Bennett. “It’s heartening to see the decline of COVID patients in our hospitals. We remain ever vigilant to not only protect New Jerseyans today, but also to build up our ability to respond to any signs of renewed virus activity.”

Other data in the review from NJHA’s Center for Health Analytics, Research and Transformation, captured through May 20, shows:

  • 150,339 N.J. residents have tested positive for the virus, which represents 1.7 percent of the state’s population. Nationally, more than 1.5 million have been infected, which represents approximately 0.45 percent of the population.
  • 10,747 N.J. residents have died from COVID-19, representing 7.1 percent of the state’s total COVID cases. Across the country, more than 90,000 individuals have died, for a national death rate at just over 6 percent.

Go to www.njha.com/CHART to view the full CHART bulletin.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.